These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 12803731)

  • 1. The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions.
    Zhao L; Bath PM; Fox S; May J; Judge H; Lösche W; Heptinstall S
    Curr Med Res Opin; 2003; 19(3):178-86. PubMed ID: 12803731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist.
    Zhao L; Bath PM; May J; Lösche W; Heptinstall S
    Platelets; 2003; 14(7-8):473-80. PubMed ID: 14713516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro.
    Scholz T; Zhao L; Temmler U; Bath P; Heptinstall S; Lösche W
    Platelets; 2002 Nov; 13(7):401-6. PubMed ID: 12487787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
    Graff J; Klinkhardt U; Harder S
    Thromb Res; 2004; 113(5):295-302. PubMed ID: 15183041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A; Wendel HP; Azevedo R; Ziemer G
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors.
    Lages B; Weiss HJ
    Br J Haematol; 2001 Apr; 113(1):65-71. PubMed ID: 11328283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression.
    Steiner S; Seidinger D; Huber K; Kaun C; Minar E; Kopp CW
    Arterioscler Thromb Vasc Biol; 2003 Sep; 23(9):1697-702. PubMed ID: 12869353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro.
    Zhao L; Bath P; Heptinstall S
    Br J Pharmacol; 2001 Sep; 134(2):353-8. PubMed ID: 11564653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
    Klinkhardt U; Kirchmaier CM; Westrup D; Graff J; Mahnel R; Breddin HK; Harder S
    Clin Pharmacol Ther; 2000 Mar; 67(3):305-13. PubMed ID: 10741635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
    Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
    Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The involvement of adhesion molecules and lipid mediators in the adhesion of human platelets to eosinophils.
    Jawień J; Lomnicka M; Korbut R; Chłopicki S
    J Physiol Pharmacol; 2005 Dec; 56(4):637-48. PubMed ID: 16391420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin.
    Schneider DJ; Baumann PQ; Holmes MB; Taatjes DJ; Sobel BE
    Thromb Haemost; 2001 Feb; 85(2):309-13. PubMed ID: 11246553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-monocyte interaction and GPIIb/IIIa blockade.
    Zhao L; Bath P; Lösche W; Heptinstall S
    Thromb Haemost; 2004 Oct; 92(4):888-90. PubMed ID: 15467921
    [No Abstract]   [Full Text] [Related]  

  • 18. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury.
    Bright JM; Dowers K; Powers BE
    Vet Ther; 2003; 4(1):35-46. PubMed ID: 12756634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.